A rational approach to androgen therapy for hypogonadal men with prostate cancer

International Journal of Impotence Research

Volumn 18, Issue 1, 2006, Pages 26-31

  Kaufman, J ^a  

^a Urology Research Options   (United States)

Author keywords

Hypogonadism; Prostate cancer; Testosterone replacement therapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN THERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SYSTEMATIC REVIEW;

ANDROGENS; HUMANS; HYPOGONADISM; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 30044445514     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901401     Document Type: Review

References (38)

1. Oefelein M. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998; 160: 1685-1688.
2. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997; 47: 727-737.
3. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab 1990; 70: 792-797.
4. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793-3796.
5. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979; 48: 955-958.
6. World Health Organization. Third International Consensus Consultation on Prostate Cancer. Paris, France, 2002.
7. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920-922.
8. Slater S, Oliver RTD. Testosterone. Its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000; 17: 431-439.
9. Shaneyfelt T, Husein R, Bubley G, Mantzoios CS. Hormonal predictors of prostate cancer; a meta-analysis. J Clin Oncol 2000; 18: 847-853.
10. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer; a quantitative review of prospective studies. Br J Cancer 1999; 80: 930-934.
11. Parsons JK, Carter HB, Lan dis P, Wright EJ, Plotz EA, Metler EJ. Higher serum free testosterone is associated with an increased risk of prostate cancer: results from the Baltimore Longitudinal Study on Aging. Proceedings from the 99th annual meeting of the American Urological Association. J Urol 2004; 171: 116. Abstract #439.
12. Massengill JC, Sun L, Moal JW, Wu H, McLeod DG, Amling C et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-1675.
13. Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935-1937.
14. Schatzl G, Madersbacher S, Hotel A, Gsur A, Pryer M, Hadinger G et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-1315.
15. Morgantaler A, Bunning III CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904-1906.
16. Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989; 149: 2365-2366.
17. Loughlin KP, Richie JP. Prostate cancer after exogenous testosterone therapy for impotence. J Urol 1997; 157: 1845.
18. Curran MJ, Bihrle III W. Dramatic rise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53: 423-424.
19. Gaylis FD, Lin DW, Ignatoff JM, Amling CF, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. J Urol 2005; 174: 534-538.
20. Gerstenbluth RE, Maniam PN, Corty EW, Seflel AD. Prostate specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922-926.
21. Wang C, Cunningham G, Dobs A, Ironmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel (Androgel), treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrin Metab 2004; 89: 2085-2098.
22. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 2002; 5: 74-86.
23. Fowler Jr JE, Whitmore WF. Considerations for the use of testosterone with systemic chemotherapy in prostate cancer. Cancer 1982; 49: 1373-1377.
24. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-523.
25. Antenor JV, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urology 2005; 66: 156-160.
26. Twiss C, Slova D, Lepor H. Outcomes for Men Younger than 50 Years undergoing Radical Prostatectomy. Urology 2005; 66: 141-146.
27. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 2005; 173: 1455-1482.
28. Kuban DA, Thames HD, Shipley WU. Defining recurrence after radiation for prostate cancer. J Urol 2005; 173: 1871-1878.
29. Sandler HM. Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy. J Urol 2004; 172: S38-S41.
30. D'Amico AV, Manola J, Loffredo M, Renshaw AA, Dellacroce A, Kantoff PW. Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer. JAMA 2004; 292: 821-827.
31. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002; 41: 113-120.
32. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-536.
33. Rhoden EL, Morgantaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of one year of treatment in men with prostatic intraepithelial neoplasm. J Urol 2003; 170: 2348-2351.
34. DeWeese TL. Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard? JAMA 2004; 292: 864-866.
35. Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000; 164: 1891-1894.
36. Gulley JL, Figg WD, Steinberg SM, Carter J, Hussain MH, Dahut WL. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005; 173: 1567-1571.
37. Brawer MK. Testosterone replacement therapy for a man with prostate cancer. Rev Urol 2004; 6(Suppl 6): S35-37.
38. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-492.